Core Viewpoint - Yuheng Pharmaceutical (002437) announced that its wholly-owned subsidiary, Pude Pharmaceutical, received approval from the National Medical Products Administration for the injection of multiple vitamins (12) [1] Group 1: Product Approval and Market Potential - The injection of multiple vitamins (12) has passed the consistency evaluation of generic drug quality and efficacy [1] - The product is intended for adult and pediatric patients aged 11 and above, with projected sales in urban public hospitals and county-level public medical institutions in China amounting to 1.916 billion yuan in 2024 [1] Group 2: R&D Investment - Pude Pharmaceutical has invested approximately 3.6706 million yuan in the consistency evaluation work for this product [1]

| | √特定对象调研□分析师会议 | | --- | --- | | 投资者关系活动 | □ 媒体采访□业绩说明会 | | 类别 | □ 新闻发布会□ 路演活动 | | | □ 现场参观 | | | □ 其他（请文字说明其他活动内容） | | 参与单位名称及 | 信达证券、大成基金、天治基金、嘉实基金、上海肇万资产、拾 | | 人员姓名 | 贝投资、天弘基金 | | 时间 | 年 月 日 2025 6 11 10:00-11:00 | | 形式 | 口现场口网上√电话会议 | | 上市公司接待人 | 董事、副总经理、董事会秘书：刘月寅 | | 员姓名 | 证券事务代表：白雪龙 | | | 问题 1：公司近年来的收入规模与 2018 年、2019 年相比 | | | 存在较大幅度的下降，主要原因是什么？ | | | 回复： | | | 主要有几点原因： | | | 1、公司于 2019 年底出售了澳诺（中国）制药有限公司 | | | 100%股权，该公司在 2020 年及之后均不再纳入到公司合并报 | | | 表范围； | | 投资者关系活动 | 2、公司部分产品如注射用磷酸肌酸钠受重点监控目录及 | | 主 ...

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2025-055 哈尔滨誉衡药业股份有限公司 关于全资下属公司与卫材（中国）药业有限公司 就甲钴胺注射液（商品名：弥可保）签订市场推广服务协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、协议签署时间及主要内容 （一）协议签署时间 2025 年 6 月 1 日，哈尔滨誉衡药业股份有限公司（以下简称"公司"）全资 下属公司天津誉衡博达科技有限公司（以下简称"天津博达"）与卫材（中国） 药业有限公司（以下简称"卫材中国药业"）就"甲钴胺注射液"（商品名：弥 可保）签订《市场推广服务协议》（以下简称"协议"）。 （二）协议主要内容 1、卫材中国药业授权天津博达在中国大陆地区（不包括香港特别行政区、 澳门特别行政区和台湾地区）独家推广甲钴胺注射液（商品名：弥可保），授权 期限自 2025 年 6 月 1 日起至协议有效期届满之日终止。 2、天津博达负责提供该产品在上述区域的市场推广服务和其他相关服务。 3、卫材中国药业将按照协议约定向天津博达支付相应的市场推广服务费。 （五 ...

Group 1 - Huapei Power received a project intention letter from a domestic new energy vehicle company for a thermal management system PTC water heater, with an estimated sales amount of approximately 9 million yuan over a 5-year lifecycle starting from 2026 [1] - Antu Biotech obtained medical device registration certificates for products including "Cytomegalovirus IgM Antibody Test Kit" [1][2] - Yihong Technology adjusted the upper limit of its share repurchase price to 65.04 yuan per share, with a total repurchase amount of 6.9583 million yuan for 198,000 shares [2] Group 2 - Aihui Long received a medical device registration certificate for the Hepatitis B virus core antibody detection kit, valid until May 28, 2030 [2][3] - Quanxin Co. plans to engage in commodity futures hedging to mitigate raw material price fluctuations, with a maximum guarantee amount of 8 million yuan [3] - Jiahua Intelligent plans to lease idle assets in Dongguan for a total rental amount of approximately 6.3193 million yuan over 6 years [3] Group 3 - Qianjiang Biochemical announced the resignation of its chairman and a director, with a new chairman to be elected [4][5] - Aerospace Morning Light was suspended from participating in military procurement activities due to violations, with internal investigations underway [6] - Guang'an Aizhong intends to establish a fund with a total scale of 70.7 million yuan, focusing on distributed wind and solar power generation [7] Group 4 - Zhejiang Medicine plans to use up to 1 billion yuan of idle funds for entrusted wealth management, with a maximum investment period of 12 months [10] - Hengrui Medicine's subsidiary received approval for clinical trials of HRS9531 injection, aimed at treating type 2 diabetes patients [11] - Taiji Co. announced the purchase of 10 million yuan in wealth management products, with a minimum holding period of 6 months [12] Group 5 - Hong Kong-listed company Huichuang Pharmaceutical received approval for the clinical trial of a spray for treating primary premature ejaculation [26][27] - Haichuang Pharmaceutical's new drug application for a prostate cancer treatment was approved by the National Medical Products Administration [28] - Zhuhai Guanyu was selected as a designated supplier for low-voltage lithium batteries by SAIC Volkswagen [29] Group 6 - Huayi Technology opened a tax refund service for overseas travelers, enhancing its retail offerings [32] - Baobian Electric plans to transfer 90% of its subsidiary's shares for 137 million yuan [33] - Yiwei Communication intends to invest 100 million yuan to establish a wholly-owned subsidiary to enhance its strategic layout [34]

证券代码：002437 证券简称：誉衡药业 公告编号：2025-054 哈尔滨誉衡药业股份有限公司 哈尔滨誉衡药业股份有限公司（以下简称"公司"）副总经理李润宝先生、 副总经理王小航先生及董事、副总经理、董事会秘书刘月寅女士保证信息披露的 内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 润宝先生计划自本公告披露之日起 15 个交易日后的三个月内以集中竞价方式减 持公司股份 587,500 股（占公司股份总数的 0.0262%）。 小航先生计划自本公告披露之日起 15 个交易日后的三个月内以集中竞价方式减 持公司股份 587,500 股（占公司股份总数的 0.0262%）。 经理、董事会秘书刘月寅女士计划自本公告披露之日起 15 个交易日后的三个月 内以集中竞价方式减持公司股份 259,619 股（占公司股份总数的 0.0116%）。 公司于 2025 年 5 月 29 日收到副总经理李润宝先生、副总经理王小航先生及 董事、副总经理、董事会秘书刘月寅女士出具的《股份减持计划告知函》。现将 有关情况公告如下： 一、拟减持股 ...

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2025-054 哈尔滨誉衡药业股份有限公司 关于公司部分董事及高级管理人员减持股份的预披露公告 哈尔滨誉衡药业股份有限公司（以下简称"公司"）副总经理李润宝先生、 副总经理王小航先生及董事、副总经理、董事会秘书刘月寅女士保证信息披露的 内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、持有公司股份 2,350,000 股（占公司总股本比例 0.1046%）的副总经理李 润宝先生计划自本公告披露之日起 15 个交易日后的三个月内以集中竞价方式减 持公司股份 587,500 股（占公司股份总数的 0.0262%）。 2、持有公司股份 2,350,000 股（占公司总股本比例 0.1046%）的副总经理王 小航先生计划自本公告披露之日起 15 个交易日后的三个月内以集中竞价方式减 持公司股份 587,500 股（占公司股份总数的 0.0262%）。 注：如计划减持期间有送股、资本公积金转增股本、配股等除权除息事项，减持股份数 量将相应进行调 ...

誉衡药业（002437）公告，副总经理李润宝、副总经理王小航及董事、副总经理、董事会秘书刘月寅计 划自公告披露之日起15个交易日后的三个月内，通过集中竞价方式减持公司股份。李润宝和王小航分别 拟减持58.75万股，各占公司总股本的0.0262%；刘月寅拟减持25.96万股，占公司总股本的0.0116%。减 持原因是个人资金需求，减持价格将按市场价格确定。 ...

医药生物行业资金流出榜 医药生物行业资金流入榜 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 300534 | 陇神戎发 | 11.29 | 27.54 | 13261.07 | | 002437 | 誉衡药业 | 9.89 | 9.40 | 12683.64 | | 603259 | 药明康德 | 0.86 | 0.88 | 12103.63 | | 000953 | 河化股份 | 9.99 | 18.71 | 12103.00 | | 000078 | 海王生物 | 9.83 | 2.63 | 7433.92 | | 300558 | 贝达药业 | 7.94 | 4.81 | 7368.93 | | 002422 | 科伦药业 | -0.45 | 1.30 | 6954.77 | | 002907 | 华森制药 | 9.98 | 2.87 | 6810.87 | | 002821 | 凯莱英 | 4.45 | 1.95 | 6219.45 | | 600216 | 浙江医药 | 3.10 | ...

Group 1 - Guangdian Electric's wholly-owned subsidiary plans to sell 5.91% stake in Shanghai Winshun Electric Technology Co., Ltd. to Yapp Automotive Parts Co., Ltd. for 62.63 million yuan, aiming to optimize asset structure [1] - Anhui Natural Gas received approval for the registration of 500 million yuan short-term financing bonds and 600 million yuan medium-term notes, valid for two years [1] - Kirin Security received government subsidies totaling 6.48 million yuan, which are related to revenue [2] Group 2 - Junshi Biosciences received approval for two new indications for its self-developed drug, Oncorhynchus monoclonal antibody injection, targeting adult patients with heterozygous familial hypercholesterolemia and non-familial hypercholesterolemia [3] - China Resources Double Crane's subsidiary passed GMP compliance inspection for small and large volume injection production lines [4] - Nanjing Public Utilities' board approved the absorption and merger of its wholly-owned subsidiary, Nanjing Jinguang Industry Co., Ltd. [7] Group 3 - Boya Bio received drug registration certificate for human immunoglobulin (pH4) in the Dominican Republic, valid until August 12, 2029 [8] - Jizhi Co. announced that its controlling shareholder and actual controller committed not to reduce their shareholdings until December 31, 2025 [9] - Yuhua Tian won a bid for the integrated urban management project in Lanzhou City, with a total service subsidy of 353 million yuan [10] Group 4 - Anke Rui obtained five invention patent certificates related to various energy management and control technologies [11] - Kebo Da's wholly-owned subsidiary plans to acquire 100% of Czech IMI Company for approximately 9.43 million euros to enhance global production layout [13] - Yantian Port announced a cash dividend of 1.30 yuan per 10 shares, totaling 676 million yuan [14] Group 5 - Huawang Technology plans to distribute a cash dividend of 0.45 yuan per share and a capital reserve increase of 0.20 shares per share [15] - Kabe Yi established a wholly-owned subsidiary in Japan to enhance its business layout [16] - Dongcheng Pharmaceutical's subsidiary received approval for the marketing of sodium fluoride injection, a PET radiopharmaceutical [18] Group 6 - Huaxin New Materials' subsidiary received two utility model patent certificates for innovative devices [19] - Lingang Steel's new 2290 cubic meter blast furnace has been successfully put into operation [21] - Xinlitai received drug registration certificate for Sacubitril/Valsartan tablets, the first of its kind in China [23] Group 7 - Aike Co.'s subsidiary received project designation notices from multiple clients for electric drive platform components [25] - Tonghe Pharmaceutical received drug registration certificate for Apixaban in South Korea [26] - Junting Hotel signed a cooperation agreement with Choice Hotels for exclusive brand usage in mainland China [28] Group 8 - Guangdong Hongtu plans to establish a wholly-owned subsidiary in Zhengzhou to enhance market layout [30] - Yuheng Pharmaceutical signed a joint promotion agreement for Pemafibrate tablets with Xinghe Pharmaceutical [31] - Chongqing Steel terminated the absorption and merger of its wholly-owned subsidiary, citing strategic advantages of independent operation [33] Group 9 - Jihong Co. announced the listing of its H-shares on the Hong Kong Stock Exchange [34] - Deshi Co. announced plans for shareholders to reduce their holdings by up to 0.3% [36] - Xinhai Medical's subsidiary received medical device registration for a dialysis fluid filter [42]

Policy Developments - The National Medical Products Administration (NMPA) has announced the implementation of the "Quality Management Standards for Online Sales of Medical Devices," effective from October 1, 2025. Regulatory authorities are required to guide online sellers and e-commerce platforms in conducting internal training and assessments related to quality management systems, product information display, and risk monitoring [2]. Drug and Device Approvals - BeiGene announced positive results from the Phase 2 clinical trial (DeLLphi-307) of tarlatamab for treating extensive-stage small cell lung cancer (ES-SCLC) patients in China, with detailed data to be presented at an upcoming medical conference [4]. Capital Market Activities - Shanghai BoYin Biotechnology Co., Ltd. has completed a multi-million angel round financing, led by Zhangjiang Life and Health Industry Incubation Angel Fund, with funds aimed at advancing the company's product pipeline and early clinical validation of its first product [7]. Industry Developments - Yuheng Pharmaceutical has signed a co-promotion agreement with Xinghe Pharmaceutical for Pemafibrate, a novel selective PPARα modulator, which will take effect on June 1, 2025. This agreement is expected to enhance Yuheng's product pipeline and potential profit growth, although it will face competition from established products [9]. Shareholder Activities - Chengdu XianDao announced that shareholder Anji Dongfang Jiayu Enterprise Management Partnership reduced its stake by 1 million shares, decreasing its ownership from 6.2% to 5.95% [12]. - BioVeda China RMB Investment Limited plans to reduce its stake in AoJing Medical by up to 135,550 shares, having already reduced its holdings by 34,510 shares, representing 0.25% of the total shares [13].